Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Orchestra Biomed Holdings Inc maintains a gross margin of 94.31%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2359.23%, while the net margin is -2419.05%. These profitability ratios, combined with a Return on Equity (ROE) of -166.97%, provide a clear picture of how effectively OBIO converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, OBIO competes directly with industry leaders such as CV and AVR. With a market capitalization of $246.19M, it holds a significant position in the sector. When comparing efficiency, OBIO's gross margin of 94.31% stands against CV's 54.10% and AVR's 70.65%. Such benchmarking helps identify whether Orchestra Biomed Holdings Inc is trading at a premium or discount relative to its financial performance.
